Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
A sarcoma is a cancer that arises from uncontrolled cell growth in tissues of mesodermal origins, such as connective tissue, bone, cartilage, fat or muscle. There are around 100 different subtypes of sarcoma that can be classified into three broad groups: soft tissue sarcoma; primary bone sarcoma; and gastro-intestinal stromal tumours.
In this phase 1 trial, Hegde et al. treat 13 individuals with advanced sarcoma with lymphodepletion followed by HER2-specific CAR T cells, which were found to be safe and showed antitumor activity.
This study presents a novel mechanism by which androgen receptor (AR) antagonists inhibit the growth of desmoplastic small round cell tumors (DSRCT) independently of AR.
Cancer associated fibroblasts can shape the tumor microenvironment (TME) and modulate immune infiltration. Here the authors characterize the TME in preclinical models of softtissue sarcomas, identifying a subset of “glycolytic” cancer-associated fibroblasts that inhibit cytotoxic T cell infiltration into the tumor parenchyma.
In this Journal Club, Góss dos Santos discusses a study that successfully generated sarcoma-derived organoids and utilized them to identify a novel therapeutic target.